Bryce Point Capital LLC acquired a new stake in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 18,479 shares of the company's stock, valued at approximately $808,000.
Other institutional investors have also recently added to or reduced their stakes in the company. IFP Advisors Inc acquired a new position in Revolution Medicines during the 4th quarter worth $34,000. Quarry LP purchased a new position in Revolution Medicines in the third quarter worth $82,000. Farther Finance Advisors LLC increased its stake in Revolution Medicines by 368.3% in the 4th quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company's stock valued at $90,000 after purchasing an additional 1,613 shares in the last quarter. Daiwa Securities Group Inc. increased its position in Revolution Medicines by 521.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 3,787 shares of the company's stock worth $165,000 after buying an additional 3,178 shares in the last quarter. Finally, Avanza Fonder AB purchased a new stake in Revolution Medicines in the 4th quarter worth approximately $173,000. Hedge funds and other institutional investors own 94.34% of the company's stock.
Revolution Medicines Price Performance
NASDAQ RVMD traded up $0.91 on Tuesday, hitting $32.31. 755,316 shares of the company were exchanged, compared to its average volume of 1,412,630. The company's 50 day moving average price is $39.42 and its 200-day moving average price is $45.15. The firm has a market capitalization of $6.01 billion, a P/E ratio of -9.00 and a beta of 1.37. Revolution Medicines, Inc. has a twelve month low of $29.17 and a twelve month high of $62.40.
Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($1.12) EPS for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.11). As a group, equities analysts expect that Revolution Medicines, Inc. will post -3.49 EPS for the current year.
Analyst Ratings Changes
Several brokerages recently commented on RVMD. HC Wainwright upped their price target on shares of Revolution Medicines from $72.00 to $73.00 and gave the stock a "buy" rating in a research report on Monday, March 3rd. Stifel Nicolaus cut their price target on Revolution Medicines from $78.00 to $64.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. UBS Group lifted their target price on Revolution Medicines from $65.00 to $71.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. Wedbush restated an "outperform" rating and set a $67.00 price objective on shares of Revolution Medicines in a research note on Thursday, February 27th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $59.00 price objective on shares of Revolution Medicines in a research report on Tuesday. Twelve equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Revolution Medicines currently has a consensus rating of "Buy" and a consensus target price of $65.23.
Check Out Our Latest Stock Report on Revolution Medicines
Insider Buying and Selling at Revolution Medicines
In related news, COO Margaret A. Horn sold 3,058 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $119,384.32. Following the completion of the transaction, the chief operating officer now directly owns 153,533 shares of the company's stock, valued at $5,993,928.32. This trade represents a 1.95 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Jack Anders sold 1,864 shares of the company's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $72,770.56. Following the completion of the sale, the chief financial officer now directly owns 115,006 shares in the company, valued at approximately $4,489,834.24. The trade was a 1.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 16,660 shares of company stock worth $650,406 over the last 90 days. 8.00% of the stock is currently owned by corporate insiders.
About Revolution Medicines
(
Free Report)
Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.
Featured Stories
Before you consider Revolution Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revolution Medicines wasn't on the list.
While Revolution Medicines currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
